Bifogade filer
Kurs
+1,06%
Likviditet
0,42 MNOK
Kalender
Tid* | ||
2026-02-19 | 13:00 | Bokslutskommuniké 2025 |
2025-11-19 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-21 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-05-20 | N/A | Årsstämma |
2025-02-26 | 13:00 | Bokslutskommuniké 2024 |
2024-11-13 | - | Kvartalsrapport 2024-Q3 |
2024-10-10 | - | Extra Bolagsstämma 2024 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-30 | - | Split BGBIO 100:1 |
2024-05-29 | - | Kvartalsrapport 2024-Q1 |
2024-05-24 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2024-05-23 | - | Årsstämma |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-11-14 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-06-22 | - | Kvartalsrapport 2023-Q1 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-15 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-05-24 | - | Kvartalsrapport 2022-Q1 |
2022-04-29 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-02-16 | - | Bokslutskommuniké 2021 |
2022-01-06 | - | Extra Bolagsstämma 2022 |
2021-11-16 | - | Kvartalsrapport 2021-Q3 |
2021-08-17 | - | Kvartalsrapport 2021-Q2 |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-03-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2021-03-19 | - | Årsstämma |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-12-09 | - | Extra Bolagsstämma 2020 |
2020-11-17 | - | Kvartalsrapport 2020-Q3 |
2020-08-18 | - | Kvartalsrapport 2020-Q2 |
2020-05-19 | - | Kvartalsrapport 2020-Q1 |
2020-03-17 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2020-03-16 | - | Årsstämma |
2020-02-11 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-19 | - | Kvartalsrapport 2019-Q2 |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-03-14 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2019-03-13 | - | Årsstämma |
2019-02-19 | - | Bokslutskommuniké 2018 |
2018-11-13 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-05-15 | - | Kvartalsrapport 2018-Q1 |
2018-05-15 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2018-05-14 | - | Årsstämma |
2018-03-09 | - | Extra Bolagsstämma 2018 |
2018-02-13 | - | Bokslutskommuniké 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-23 | - | Kvartalsrapport 2017-Q1 |
2017-03-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2017-03-22 | - | Årsstämma |
2016-06-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2016-06-21 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
Bergen, Norway - 19 September 2024: BerGenBio ASA (OSE:BGBIO) will be holding a Extraordinary General Meeting virtually on 10 October 2024 at 10:00 hours (CEST).
The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company's website: https://www.bergenbio.com/investors/general-meetings/
All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the person he appoints), or to attend the general meeting virtually.
Advance vote or proxy for the Annual General Meeting can be registered through the company's website (https://www.bergenbio.com/investors/general-meetings/) or VPS Investor Service (https://investor.vps.no/gm/logOn.htm?token=1c142f482991b4042a7a7f81406dafb4ce5e515d&validTo=1731139200000&oppdragsId=20240916VPK455U0) within 8 October 2024 16:00 hours (CEST). Virtual participants need to be logged in to the meeting before 10:00 hours (CEST) 10 October 2024.
All shareholders will receive a reference number and a pin code required for registration through the company's website. Reference number and pin code will be received either by VPS Investor Service or by post depending if the shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS.
- END -
AboutBerGenBioASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Contacts
Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.